Selective Estrogen Receptor Modulators

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cancer Research

• Publication date

  2004-02-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-03-3326PMID 14973112
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain

  2004cited by this paper
• Differential SERM Effects on Corepressor Binding Dictate ERα Activity in Vivo *

  2003cited by this paper
• Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.

  2003cited by this paper
• The gene expression response of breast cancer to growth regulators: patterns and correlation with tumor expression profiles.

  2003cited by this paper
• Gene expression predictors of breast cancer outcomes.

  2003cited by this paper
• Molecular classification of familial non-BRCA1/BRCA2 breast cancer

  2003cited by this paper
• Global transcription profiling of estrogen activity: estrogen receptor alpha regulates gene expression in the kidney.

  2003cited by this paper
• National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.

  2003cited by this paper
• Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.

  2003cited by this paper
• Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype.

  2003influential reference
• Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells.

  2003cited by this paper
• Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells.

  2003cited by this paper
• Differential SERM effects on corepressor binding dictate ERalpha activity in vivo.

  2003cited by this paper
• Molecular Determinants for the Tissue Specificity of SERMs

  2002cited by this paper
• Combinatorial control of gene expression by nuclear receptors and coregulators.

  2002cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines.

  2002cited by this paper
• Testosterone and 5α-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines

  2002cited by this paper
• A study of estrogen signaling using DNA microarray in human breast cancer

  2002cited by this paper
• Breast cancer: from estrogen to androgen receptor

  2002cited by this paper
• Identification of RB1CC1, a novel human gene that can induce RB1 in various human cells

  2002cited by this paper
• Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer

  2002cited by this paper
• Gene expression in inherited breast cancer.

  2002cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper
• Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators

  2002cited by this paper
• Defining the "S" in SERMs

  2002cited by this paper
• Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators.

  2002cited by this paper
• Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays

  2002cited by this paper
• Truncating mutations of RB1CC1 in human breast cancer

  2002cited by this paper
• Biomedicine. Defining the "S" in SERMs.

  2002cited by this paper
• Requirement of Estrogen Receptor-α in Insulin-like Growth Factor-1 (IGF-1)-induced Uterine Responses and in Vivo Evidence for IGF-1/Estrogen Receptor Cross-talk*

  2002cited by this paper
• Suppression of the transformed phenotype of breast cancer by tropomyosin-1.

  2002cited by this paper
• Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor.

  2002cited by this paper
• Predicting the clinical status of human breast cancer by using gene expression profiles

  2001cited by this paper
• Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells.

  2001cited by this paper
• From Adjuvant Therapy to Breast Cancer Prevention: BCPT and STAR

  2001cited by this paper
• Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns.

  2001cited by this paper
• Structure and mechanism of the oestrogen receptor.

  2001cited by this paper
• 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions.

  2001cited by this paper
• Genes that co-cluster with estrogen receptor alpha in microarray analysis of breast biopsies

  2001cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial

  2000cited by this paper
• An issue of tissues: divining the split personalities of selective estrogen receptor modulators

  2000cited by this paper
• Similarities and distinctions in the mode of action of different classes of antioestrogens.

  2000cited by this paper
• Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription.

  2000cited by this paper
• Ligand-, Cell-, and Estrogen Receptor Subtype (α/β)-dependent Activation at GC-rich (Sp1) Promoter Elements*

  2000cited by this paper
• Müllerian Inhibiting Substance Inhibits Breast Cancer Cell Growth through an NFκB-mediated Pathway*

  2000cited by this paper
• Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway.

  2000cited by this paper
• A Pure Estrogen Antagonist Inhibits Cyclin E-Cdk2 Activity in MCF-7 Breast Cancer Cells and Induces Accumulation of p130-E2F4 Complexes Characteristic of Quiescence*

  2000cited by this paper
• The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial

  2000cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements.

  2000cited by this paper
• Combinatorial roles of the nuclear receptor corepressor in transcription and development.

  2000cited by this paper
• An Antiestrogen-responsive Estrogen Receptor-α Mutant (D351Y) Shows Weak AF-2 Activity in the Presence of Tamoxifen*

  2000cited by this paper
• Peptide antagonists of the human estrogen receptor.

  1999cited by this paper
• Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

  1999cited by this paper
• Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.

  1999cited by this paper
• The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.

  1999cited by this paper
• The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions.

  1999cited by this paper
• Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist

  1999cited by this paper
• Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.

  1999cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.

  1998cited by this paper
• Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.

  1998cited by this paper
• Estrogen Response Elements Can Mediate Agonist Activity of Anti-estrogens in Human Endometrial Ishikawa Cells*

  1998cited by this paper
• Tamoxifen in the treatment of breast cancer.

  1998cited by this paper
• Tamoxifen in the Treatment of Breast Cancer

  1998cited by this paper
• The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens.

  1997cited by this paper
• Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen.

  1997cited by this paper
• Different Residues of the Human Estrogen Receptor Are Involved in the Recognition of Structurally Diverse Estrogens and Antiestrogens*

  1997cited by this paper
• Molecular basis of agonism and antagonism in the oestrogen receptor

  1997cited by this paper
• Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.

  1997cited by this paper
• The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT.

  1997cited by this paper
• We regret to inform you.

  1997cited by this paper
• Identification of Amino Acids in the Hormone Binding Domain of the Human Estrogen Receptor Important in Estrogen Binding*

  1996cited by this paper
• Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor.

  1996cited by this paper
• Different Regions in Activation Function-1 of the Human Estrogen Receptor Required for Antiestrogen- and Estradiol-dependent Transcription Activation*

  1996cited by this paper
• Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity.

  1996cited by this paper
• Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.

  1996cited by this paper
• Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor.

  1995cited by this paper
• Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens.

  1995cited by this paper
• Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic adenosine 3',5'-monophosphate, estradiol, insulin-like growth factor-I, and serum factors.

  1994cited by this paper
• Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription.

  1994cited by this paper
• Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover.

  1992cited by this paper
• Progesterone receptor regulation in uterine cells: stimulation by estrogen, cyclic adenosine 3',5'-monophosphate, and insulin-like growth factor I and suppression by antiestrogens and protein kinase inhibitors.

  1991cited by this paper
• Role of the two activating domains of the oestrogen receptor in the cell‐type and promoter‐context dependent agonistic activity of the anti‐oestrogen 4‐hydroxytamoxifen.

  1990cited by this paper
• Tamoxifen in the treatment of breast cancer.

  1988cited by this paper
• Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2 2 DD C T Method

  year unknowncited by this paper

• Microglia Rank signaling regulates GnRH function and the Hypothalamic-Pituitary-Gonadal axis

  2026cites this paper
• Multidimensional regulation of estrogen signaling in pelvic floor connective tissue homeostasis and remodeling

  2026influential citation
• Mutational landscapes of HNF MODY gene products display a wide distribution with functional implications

  2025cites this paper
• Selective Estrogen Receptor Modulators (SERMs) in non-cancer therapeutics: expanding horizons beyond oncology

  2025cites this paper
• Unraveling the hormonal approaches for the treatment of rheumatoid arthritis and its complementary interventions

  2025influential citation
• Clomiphene-Induced Severe Hypertriglyceridemia and Acute Pancreatitis: A Case Report and Literature Review

  2025cites this paper
• The sex hormone-gut microbiome axis: mechanistic drivers of sex-disparate bacterial infection outcomes and precision clinical interventions

  2025cites this paper
• Targeting estrogen receptor alpha in breast cancer for novel therapies resistance mechanisms and future directions

  2025cites this paper
• LINC00626 drives tamoxifen resistance in breast cancer cells by interaction with UPF1

  2025cites this paper
• The Risk of Cardiovascular Disease following Aromatase Inhibitor Therapy for Breast Cancer in Postmenopausal Women: A Systematic Review and Meta-Analysis

  2025cites this paper
• The impact of tamoxifen on apolipoproteins and lipoprotein(a) levels: an updated meta-analysis of randomized controlled trials

  2025cites this paper
• Phenoxyalkyl cyclic and acyclic amine derivatives: what do they teach us about scaffold-based drug design?

  2024cites this paper
• Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021–December 2023)

  2024cites this paper
• Exploring the Complex Mechanisms of Isoflavones: From Cell Bioavailability, to Cell Dynamics and Breast Cancer

  2024cites this paper
• IS SARM - Selective Androgen Receptor Modulator: A Chance for Therapeutic Approach in Muscle-Wasting Chronic Conditions?

  2024cites this paper
• Screening to prevent osteoporotic fractures in Egypt: a position statement of the Egyptian Academy of Bone Health

  2024cites this paper
• Oestrogen receptor positive breast cancer and its embedded mechanism: breast cancer resistance to conventional drugs and related therapies, a review

  2024cites this paper
• Targeting unique ligand binding domain structural features downregulates DKK1 in Y537S ESR1 mutant breast cancer cells

  2024cites this paper
• Insights into Dysregulated Neurological Biomarkers in Cancer

  2024cites this paper
• Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S ESR1 Mutant Breast Cancer Cells

  2024cites this paper
• The effect of tamoxifen as an adjuvant therapy for breast cancer on apolipoproteins and lipoprotein(a) concentrations in women: A meta-analysis of randomized controlled trials.

  2024cites this paper
• Experimental and clinical evidence in favour of an effective immune stimulation in ER-positive, endocrine-dependent metastatic breast cancer

  2024cites this paper
• Endocrine therapy plus HER2-targeted therapy, another favorable option for HR+/HER2+ advanced breast cancer patients

  2024cites this paper
• Pathological Changes Following Neoadjuvant Endocrine Therapy (NAET): A Multicentre Study of 391 Breast Cancers

  2024cites this paper
• Urolithin A: A promising selective estrogen receptor modulator and 27‐hydroxycholesterol attenuator in breast cancer

  2023cites this paper
• Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype

  2023cites this paper
• Estradiol and Mu opioid-mediated reward: The role of estrogen receptors in opioid use

  2023cites this paper
• Using sequential pharmacotherapy for the treatment of osteoporosis: an update of the literature

  2023cites this paper
• New Concepts in Cardio-Oncology.

  2023cites this paper
• Retrospective on Structure Activity Relationships with a Focus on Tamoxifen in the Treatment of Breast Cancer

  2023cites this paper
• Genomics-based tools for drug discovery and development: From network maps to efficacy prediction

  2023cites this paper
• Combination of tamoxifen and D-limonene enhances therapeutic efficacy in breast cancer cells

  2023cites this paper
• Oral Therapeutics Post Menopausal Osteoporosis

  2023cites this paper
• A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer

  2023cites this paper
• Small Change - Big Consequence: The Impact of C15-C16 Double Bond in a D‑ring of Estrone on Estrogen Receptor Activity.

  2023cites this paper
• From Cells to Environment: Exploring the Interplay between Factors Shaping Bone Health and Disease

  2023cites this paper
• Systems genetics and bioinformatics analyses using ESR1-correlated genes identify potential candidates underlying female bone development

  2023cites this paper
• Gene transcription regulation by ER at the single cell and allele level.

  2023cites this paper
• A comprehensive update of hormone-related pharmacokinetic variations associated with breast cancer drugs

  2023cites this paper
• Cardiotoxicity of Agents Used in Patients With Breast Cancer.

  2023cites this paper
• A Mixture of Cervus elaphus sibiricus and Glycine max (L.) Merrill Inhibits Ovariectomy-Induced Bone Loss Via Regulation of Osteogenic Molecules in a Mouse Model

  2023cites this paper
• Tau and stathmin proteins in breast cancer: A potential therapeutic target

  2022cites this paper
• Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy

  2022cites this paper
• Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response.

  2022cites this paper
• Fracture risk and assessment in adults with cancer

  2022cites this paper
• Tamoxifen Twists Again: On and Off-Targets in Macrophages and Infections

  2022cites this paper
• Modulatory Effect of Gut Microbiota on the Gut-Brain, Gut-Bone Axes, and the Impact of Cannabinoids

  2022cites this paper
• Effects of chronic tamoxifen treatment in female rat sexual behaviour

  2022cites this paper
• Transcriptome analysis of human mammary epithelial cells treated with bisphenol A and bisphenol A analogue mixtures reveals major alterations in multiple cellular pathways

  2022cites this paper
• STUDY EFFECT OF TAMOXIFEN ON CELL CYCLE PHASE DISTRIBUTION, IN BREAST CANCER CELLS

  2022cites this paper
• RET signaling pathway and RET inhibitors in human cancer

  2022cites this paper
• Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy

  2022cites this paper
• The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens

  2022cites this paper
• Unequivocal Dyad of Gut Microbiome and Osteo Integrity- Dynamic Cross-Talk and Implications in Osteoporosis Management

  2022cites this paper
• Breast Cancer and the Cardiovascular Disease: A Narrative Review

  2022cites this paper
• Cortisol Response in Breast Cancer: The Role of Physical Activity and Exercise

  2022cites this paper
• Osteoporotic Fractures among Selective Estrogen Receptor Modulator Users in South Korea: Analysis Using National Claims Database

  2022cites this paper
• Evaluating the Robustness of Connectivity Methods to Noise for In Silico Drug Repurposing Studies

  2022cites this paper
• Improving DXA Quality by Avoiding Common Technical and Diagnostic Pitfalls: Part 1

  2022cites this paper
• New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies

  2022cites this paper
• ANALYSIS OF UTERINE MORPHOLOGY IN OVARIECTOMIZED RATS TREATED WITH ALENDRONATE AND HOP EXTRACT USING OPEN-SORUCE SOFTWARE

  2022cites this paper
• Role of Conformational Dynamics and Flexibilities in the Steroid Receptor- Coregulator Protein Complex Formation.

  2021cites this paper
• Facile and Efficient Synthesis of 9-Aryl-1,8-Dioxo-Octahydroxanthenes Catalyzed by Sulfacetamide

  2021cites this paper
• Pharmacotherapeutic options for the treatment of menopausal symptoms

  2021cites this paper
• High efficacy of tamoxifen-loaded L-lysine coated magnetic iron oxide nanoparticles in cell cycle arrest and anti-cancer activity for breast cancer therapy

  2021influential citation
• Crataegus pinnatifida Bunge Inhibits RANKL-Induced Osteoclast Differentiation in RAW 264.7 Cells and Prevents Bone Loss in an Ovariectomized Rat Model

  2021cites this paper
• Dichotomous Role of Microtubule Associated Protein Tau as a Biomarker of Response to and a Target for Increasing Efficacy of Taxane Treatment in Cancers of Epithelial Origin.

  2021cites this paper
• Cancer Treatment–Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy

  2021cites this paper
• Hibiscus sabdariffa anthocyanins are potential modulators of estrogen receptor alpha activity with favourable toxicology: a computational analysis using molecular docking, ADME/Tox prediction, 2D/3D QSAR and molecular dynamics simulation

  2021cites this paper
• Summary of reference chemicals evaluated by the fish short‐term reproduction assay, OECD TG229, using Japanese Medaka, Oryzias latipes

  2021cites this paper
• The Breast Cancer Stem Cells Traits and Drug Resistance

  2021cites this paper
• A comprehensive review on anticancer mechanism of bazedoxifene

  2021cites this paper
• Evaluation of protein functionalized gold nanoparticles to improve tamoxifen delivery: synthesis, characterization, and biocompatibility on breast cancer cells

  2021cites this paper
• The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density

  2021cites this paper
• Quinolino-1,8- naphthyridine derivatives: Synthesis, biological studies, DFT calculation and molecular docking with Ras protein

  2021cites this paper
• Molecular markers associated with the outcome of tamoxifen treatment in estrogen receptor-positive breast cancer patients: scoping review and in silico analysis

  2021cites this paper
• G Protein-Coupled Estrogen Receptor in Cancer and Stromal Cells: Functions and Novel Therapeutic Perspectives

  2021cites this paper
• Mitochondrial stress adaptation promotes resistance to aromatase inhibitor in human breast cancer cells via ROS/calcium up-regulated amphiregulin-estrogen receptor loop signaling.

  2021cites this paper
• Intestinal epithelial glucocorticoid receptor promotes chronic inflammation–associated colorectal cancer

  2021cites this paper
• Osteoporosis: Diagnosis and Management

  2021cites this paper
• UNDERSTANDING THE ROLE OF ARGLU1 IN INTERFERON SIGNALING ACTIVATION IN BREAST CANCER

  2021cites this paper
• Design, Synthesis and Biological Evaluation of Morpholinated Isatin-Quinoline Hybrids as Potential Anti-Breast Cancer Agents.

  2021cites this paper
• Endogenous and Therapeutic Estrogens: Maestro Conductors of the Microenvironment of ER+ Breast Cancers

  2021cites this paper
• The Development of Molecular Biology of Osteoporosis

  2021cites this paper
• Studi Penambatan Molekuler Senyawa Bioaktif Biji Habbatussauda (Nigella sativa) terhadap ERα sebagai Alternatif Pengobatan Kanker Payudara dalam Upaya Pemberian Data Ilmiah Thibbun Nabawi

  2021cites this paper
• Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients

  2021cites this paper
• Ocular Toxicity of Targeted Anticancer Agents

  2021cites this paper
• Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection

  2021cites this paper
• COVID-19: Sleep, Circadian Rhythms and Immunity – Repurposing Drugs and Chronotherapeutics for SARS-CoV-2

  2021cites this paper
• Suppression of Inflammation, Osteoclastogenesis and Bone Loss by PZRAS Extract

  2020cites this paper
• PROTECTIVE EFFECTS OF VIRGIN COCONUT OIL AND TOCOTRIENOL-RICH FRACTION ON BONE BIOMECHANICS

  2020cites this paper
• Managing therapeutic resistance in breast cancer: from the lncRNAs perspective

  2020cites this paper
• Bazedoxifene Suppresses Intracellular Mycobacterium tuberculosis Growth by Enhancing Autophagy

  2020cites this paper
• Environmental Toxicology and Chemistry

  2020cites this paper
• Minimal residual disease in advanced or metastatic solid cancers: the G0-G1 state and immunotherapy are key to unwinding cancer complexity.

  2020cites this paper
• Norlichexanthone purified from plant endophyte prevents postmenopausal osteoporosis by targeting ERα to inhibit RANKL signaling

  2020cites this paper
• Design, synthesis and anticancer/antiestrogenic activities of novel indole-benzimidazoles.

  2020cites this paper
• Controlled Ovarian Stimulation Protocols Alter Endometrial Histomorphology and Gene Expression Profiles

  2020cites this paper
• Red clover and lifestyle changes to contrast menopausal symptoms in premenopausal patients with hormone-sensitive breast cancer receiving tamoxifen

  2020cites this paper
• G Protein-Coupled Estrogen Receptor 1 Knockout Deteriorates MK-801-Induced Learning and Memory Impairment in Mice

  2020cites this paper